



Building bones for blood and beyond: the growing field of bone marrow niche model development


Current BM models




2D co-culture




Spheroid
co-culture



Biomimetic
scaffolds




BM-on-a-chip




Organoids

Future BM models



Body-on-a-chip



In silico



HSC



MSC
spheroid




Full human model



MSC



MSC (3D)



BM mimetic
scaffold



Organoid of
multiple cell types

Building bones for blood and beyond: the growing field of bone marrow niche model development



W. Sebastian Doherty-Boyd^{*1}, Hannah Donnelly[†], Monica P. Tsimbouri^{*}, and Matthew J. Dalby^{*}

^{*}*The Centre for the Cellular Microenvironment (CeMi), University of Glasgow, Glasgow, United Kingdom;*

[†]*School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom*

The bone marrow (BM) niche is a complex microenvironment that provides the signals required for regulation of hematopoietic stem cells (HSCs) and the process of hematopoiesis they are responsible for. Bioengineered models of the BM niche incorporate various elements of the in vivo BM microenvironment, including cellular components, soluble factors, a three-dimensional environment, mechanical stimulation of included cells, and perfusion. Recent advances in the bioengineering field have resulted in a spate of new models that shed light on BM function and are approaching precise imitation of the BM niche. These models promise to improve our understanding of the in vivo microenvironment in health and disease. They also aim to serve as platforms for HSC manipulation or as preclinical models for screening novel therapies for BM-associated disorders and diseases. © 2024 International Society for Experimental Hematology. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>)

HIGHLIGHTS

- Bone marrow (BM) models are becoming increasingly biomimetic.
- These models help investigate the impact of BM elements on hematopoiesis.
- Future models could enhance therapies for BM-associated disorders and diseases.

INTRODUCTION

Models of the bone marrow (BM) niche promise to not only revolutionize our understanding of both physiologic and pathologic hematology and immunology but also facilitate therapeutic advancements targeting BM-associated disorders and diseases. One of the primary goals of these niches is to manipulate hematopoietic stem cells (HSCs), a rare population of cells (~0.01%–0.04% of total BM mononuclear cells) [1], which reside within the niche and are responsible for the process of hematopoiesis, the continuous production of blood and immune cells throughout an organism's life [2]. HSCs exist in a hierarchy at the top of which sits naïve, long-term hematopoietic stem cells (LT-HSCs), a self-renewing, multipotent subpopulation of HSCs that lasts for an individual's entire lifespan [3,4] and is responsible for the production of more proliferative progenitors [5,6]. LT-HSCs maintain long-term engraftment capacity [7–9] and are critically important for hematopoietic stem cell transplant (HSCT), a curative treatment for BM malignancies and disorders [10–13].

Occasionally, LT-HSCs will produce short-term hematopoietic stem cells (ST-HSCs) via asymmetrical cell division [14]. ST-HSCs are more metabolically and mitotically active than LT-HSCs and possess reduced repopulation capacity [3]. ST-HSCs differentiate into multipotent progenitors (MPPs), which in turn produce lineage restricted progeny via an oligopotent cell step [1,15].

The BM niche itself is a highly complex organ. It maintains the HSC pool and hematopoietic homeostasis using a variety of stimuli. The niche is found within the lumen of long and axial bones [16] and is permeated by a network of tiny blood vessels [17–19]. Advances in in vivo imaging techniques have demonstrated that around this vasculature, there exists two BM “subniches,” named the sinusoidal and arteriolar niches after the blood vessels they are located around. Sinusoids carry deoxygenated blood and are distributed throughout the softer central BM cavity [17], while arterioles carry oxygenated blood and are primarily found close to the stiff endosteum's surface [20]. Despite conflicting evidence regarding the exact position of HSCs within the BM [18,19], these subniches are strongly believed to influence the HSCs that reside within them, with the arteriolar niche enriched for LT-HSCs, although a larger total HSC population is found in the sinusoidal niche [20]. Various nonhematopoietic cell types also reside within the BM niche and have been demonstrated to influence HSC function and maintenance (Table 1) [21–61]. Another important component of the BM niche is the extracellular matrix (ECM) [54], which interacts with cells via nonuniform distribution of ECM proteins such as collagen, fibronectin, and laminin [62], as well as variable mechanical properties within a characteristically low-stiffness range [63–65]. In addition, oxygen saturation plays a key role in the niche's interaction with HSCs [66,67], as does blood

Address correspondence to W. Sebastian Doherty-Boyd, The Centre for the Cellular Microenvironment (CeMi), Advanced Research Centre level 4, University of Glasgow, Glasgow G11 6EW, United Kingdom;; E-mail: w.doherty-boyd.1@research.gla.ac.uk

0301-472X/© 2024 International Society for Experimental Hematology. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>)

<https://doi.org/10.1016/j.exphem.2024.104232>

Table 1 BM niche cellular components' roles within the BM niche.

BM niche cell type	Role of cell type	References
HSCs	HSCs are responsible for hematopoiesis. They produce hematopoietic cells that regulate and form the blood and immune systems	1–19,16
MSCs	MSCs reside near HSCs in the BM niche. Nestin+ MSCs are particularly important, as they produce many of the paracrine signals associated with HSC maintenance	21–38
Osteoblasts	Osteoblasts have been hypothesized to regulate hematopoiesis through paracrine and juxtacrine signaling. However, recent studies demonstrated that HSCs do not spatially associate with osteoblasts and that osteolineage cells do not significantly contribute to the signaling milieu that influences HSC maintenance	21,23,25,33,36,39–42
Osteoclasts	Osteoclasts influence MSCs, allowing them to attract HSCs for colonization of the nascent BM niche during development. They also remodel the perinatal niche and aid with vascularization	43,44
Macrophages	Macrophages produce several soluble factors and present surface antigens that influence hematopoiesis in a paracrine and juxtacrine manner, respectively	45,46
Endothelial cells	HSCs colocalize with vasculature in the in vivo BM niche. There is a possibility that these cells influence HSCs	23,28,31,33–36,48–51
Megakaryocytes	Megakaryocytes are derived from HSC progenitors, produce platelets, regulate HSC fate, and interact with many cells within the BM niche, contributing to its regulation	52
Fibroblasts	Fibroblasts provide mechanical/physical support to HSCs during proliferation and differentiation by secreting and modulating the ECM	53,54
Adipocytes	Adipocytes have potential suppressive effects on hematopoiesis within the bone marrow niche	55
Nervous cells	Sympathetic nerves have been implicated in HSC mobilization, maintenance, and recovery following genotoxic insult	56–61

BM, bone marrow; ECM, extracellular matrix; HSC, hematopoietic stem cell; MSC, mesenchymal stromal cell.

flow [68–70]. Noncellular elements of the BM niche, their role within the niche, and how they have been used in model BM niches are summarized in Table 2 [20,21,24,25,27,28,30–38,50,71–79].

Other extramedullary sites of hematopoiesis exist over the course of development [80,81] and have been observed in response to acute hematopoietic stress [81,82]. Although these niches are spatially distinct from the BM niche, many similarities are observed; they are highly vascularized and populated by stromal and endothelial cells with similar protein expression profiles to those observed in the BM niche [82–84]. While this review will focus on BM niche models, research on these alternative hematopoietic sites could further elucidate the precise mechanisms of hematopoiesis and provide new avenues for its manipulation [85].

BM niche models emulate the in vitro BM niche. The current gold standard for BM models are animal models [86,87]. However, a lack of comparability with human biology, complexity obscuring specific mechanisms of the niche, and a lack of reproducibility and availability [54,88] hamper the success of animal models. Bioengineered in vitro BM models that replicate aspects of the BM niche are now emerging as a viable alternative. Early in vitro BM niche models aimed to expand HSCs for HSCT (reviewed in [4,89]). However, this ambition was met with mixed results, primarily due to expanded HSCs' heterogeneity, with the cells produced mostly being ST-HSCs, MPPs, and lineage-restricted progenitors, leading to reduced long-term engraftment capacity [90]. A few recent systems successfully demonstrated the plausibility of HSC expansion without the associated loss of engraftment capacity, yet these systems lack integration of the physical and functional properties of the BM niche, instead relying on

small molecules or hydrogels [91]. Over the past decade, in vitro niche models have shifted their objective away from HSC expansion and toward accurately replicating aspects of the BM niche to shed light on the hematopoietic process, harnessing it for clinical applications, and understanding how it goes wrong in hematologic diseases and disorders [22]. Foundational research in simple in vitro and animal models, combined with recent advances in the tissue engineering and hematology fields, has galvanized in vitro BM niche model development. This has resulted in a wealth of new models, the current state of which will be discussed (Figure 1A), as well as potential applications and the future of the field (Figure 1B).

CURRENT STATE OF BM NICHE MODELS

MSCs and Soluble Factors

Developing models of the BM niche for studying and manipulating normal and pathologic hematopoiesis presents various challenges, not least of which being that HSCs rapidly differentiate when cultured under standard tissue culture conditions [92]. To counteract this, soluble factors are often used. Soluble factors found within the niche promote maintenance and expansion within the putative HSC compartment [93,90,94–96]. Stem cell factor (SCF) [97], fms-like tyrosine kinase 3 (Flt3) ligand (FL) [98], and thrombopoietin (TPO) [99] have been implicated in HSC maintenance and are used routinely for HSC culture in vitro [27,37,100,101]. Of note, systems that solely used soluble factors showed limited success in growing HSCs with long-term engraftment capacity [90,94,95]. The earliest of these

Table 2 BM niche components and their impact when included in niche models.		
Model BM niche element	Impact of the element	References
BM niche cells	Inclusion of BM resident cells simulates the complex cellular composition of the BM niche, with included cells interacting with HSCs via juxtracrine and/or paracrine signaling	20,21
Soluble factors/ cytokines	The use of soluble factors has been shown to improve HSC proliferation; however, often the expanded cells are in the ST-HSC or progenitor compartment and lack long-term engraftment capacity	25,28,71–73
ECM components	ECM components such as fibronectin, collagens, vitronectin, and laminin have been shown to affect MSCs’ and HSCs’ phenotypes by sequestering and presenting signaling molecules and growth factors, as well as interacting with the cells mechanically	37,74,75
Hydrogel	BM is a low-stiffness natural hydrogel. The use of hydrogels allows the 3D nature of the in vivo BM niche to be replicated. Gels can also provide physical, mechanical, and chemical stimuli to cells in a BM niche model	27,28,31,34,36, 37,50,76
Nonhydrogel scaffold	Nonhydrogel scaffolds that mimic the structure of cortical bone, such as ceramaics, colloidal crystals, and hydroxyapatite, possess many of the same 3D benefits as hydrogels and afford the opportunity to add other properties, such as control over cellular localization, e.g., using magnetized cells and a magnetized scaffold	21,30,35
Decellularized matrix	Using decellularized animal BM matrix to culture human BM cells has met with success owing to the conserved BM architecture and physical properties	24,25,32
Blood flow/ perfusion	Perfusion models replicate blood flow, which could impact HSCs that natively reside alongside blood vessels. HSCs may also enter the circulatory system, making this another important element of the BM niche	27,30,33–36, 38,77–79

BM, bone marrow; ECM, extracellular matrix; HSC, hematopoietic stem cell; MSC, mesenchymal stromal cell; ST, short-term.




Figure 1 Illustrations of (A) current and (B) potential future bone marrow niche models. Created with BioRender.com.

systems sought to identify and deploy the source of these soluble factors. This resulted in the discovery of a secondary, adherent cell type present in the BM niche without which the HSCs were unable to survive [102]. We now know that these cells are mesenchymal stromal cells (MSCs), which interact with HSCs and maintain hematopoietic homeostasis through excreted soluble factors and juxtacrine signaling [103,104]. As a result, many modern BM niche models include MSCs.

MSCs included in BM models have several sources. MSCs sourced directly from donors' BM are the gold standard, but they are difficult to acquire owing to their relative rarity within the niche, as well as low availability of high quality BM samples from young, healthy patients [105–108]. Extramedullary sources of MSCs from patients include adipose tissue [109], peripheral blood [110], and birth-associated tissues [111]. MSCs can be acquired easily from these sources after liposuction, after birth, or a blood sample, and MSCs are more abundant in these locations, making them a popular alternative to BM MSCs [106]. Induced pluripotent stem cell (iPSC)-derived MSCs also present various advantages, namely that they can be grown from patients' somatic cell and have the potential to self-organize and reproduce various cellular aspects of the BM niche simultaneously [112,113]. However, this technology is relatively new, and more research is required before iPSC pluripotency can be fully understood and manipulated to reliably produce MSCs [114,115]. Immortalized MSCs, which are easy to use due to their long-term maintenance of differentiation competency, have been used as a BM MSC alternative as well [116].

Lima et al. [26] attempted to expand HSCs from umbilical cord blood by coculturing cord blood samples with BM-derived MSCs and various cytokines. They demonstrated remarkable expansion of putative HSCs using this method. However, when the expanded cells were transplanted into patients, long-term engraftment was significantly lower than that for transplantation with unmanipulated cord blood. These results suggested that a simple two-dimensional (2D) coculture system was insufficient to support the maintenance of the LT-HSC population that is required for successful long-term engraftment [2].

Later research attempted to improve on simple coculture models by assembling MSCs into spherical masses, termed spheroids, before coculture [22,117]. Spheroid MSCs adopted a more niche-like phenotype than those cultured in a monolayer [118,119]; however, the number of putative HSCs after expansion was shown by one study to be comparable when MSC spheroids or monolayers were used for coculture [29]. Other studies reported a substantial increase in putative HSC count under similar conditions [104,118]. This was largely attributed to soluble factors produced by the MSCs, rather than juxtacrine signaling. The advent of spheroids in BM niche models demonstrated the advantages of integrating the stromal cell component of the BM niche in 3D.

Physical Properties of the Cellular Microenvironment

Material properties, such as stiffness, porosity, and topography of HSCs' microenvironment directly affects their maintenance and proliferation [120]. Various approaches have sought to capitalize on this, for example, by using decellularized BM [24,25,32] or 3D BM mimetic scaffolds [21,30,121] to influence HSCs. An early example of this was the study by Nichols et al. [21], which used inverted colloidal crystals to mimic the porosity and stiffness of the *in vivo* BM niche

and demonstrated that this system was capable of expanding HSCs, with the inclusion of MSCs. Raic et al. [121] improved upon this approach using biofunctionalized macroporous hydrogels seeded with MSCs, resulting in a system that was capable of transient maintenance of seeded HSCs' differentiation capacity. Collectively, these models illustrated the need to incorporate BM mimetic materials into future BM niche models, as well as the combinatorial effect of materials coupled with soluble factors. Interestingly, Raic et al. [121] found a population of HSCs that did not remain within the scaffold and instead settled underneath it. They demonstrated that this cell population had much higher levels of naivety and differentiation capacity than HSCs that remained within the niche, implying the simulation of multiple BM niche compartments, which differentially influenced the HSCs within, akin to the subniches observed in the native BM niche.

The Multifaceted Nature of the BM Niche

Bourgine et al. [30] also encapsulated some of the complexity of the BM niche using a porous hydroxyapatite scaffold functionalized with human MSCs. MSCs were grown within the scaffold, causing them to deposit elements of the native BM ECM. This system was assembled in a perfusion bioreactor that mimicked the blood flow present within the *in vivo* BM niche. HSCs were added to this system, filling the scaffold and overflowing above it to form separate artificial ECM and supernatant environments, similar to the static subniches observed by Raic et al. [121]. However, unlike Raic et al. [121], Bourguine et al. [30] demonstrated that a higher proportion of the HSCs found within the scaffold displayed surface markers typically associated with LT-HSCs. It is possible that the artificial ECM compartment, which was designed to mimic the structure of bone, assumed the role of the arteriolar niche, with putative, more quiescent HSCs preferentially localizing within it, while more actively dividing HSCs localized to the supernatant. Similar models favored this assessment [36,76]. These two-compartment models replicated the multifaceted nature of the BM niche and could help to elucidate some of its complexities.

Combinatorial Niche Models

In an attempt to encapsulate various other aspects of the BM niche, some researchers have focused on engineering BM-on-a-chip models. Nelson et al. [36] created a system using a complex coculture of MSCs, osteoblasts, human umbilical vein endothelial cells, and HSCs. These cells were cultured in separate wells connected via microfluidic channels, allowing nutrient exchange between them. Different combinations of cells and media with or without the inclusion of a hydrogel were applied to each well during the assembly of the model, resulting in an interconnected system of wells each of which simulated some aspect of the *in vivo* BM niche, including angiogenesis. A similar model developed by Glaser et al. [38] incorporated perfusion as well. These highly complex systems and others like them [31,34] encompassed more BM niche elements and were more biomimetic than the simpler models discussed. This makes them excellent candidates for furthering our understanding of the BM niche in both a healthy and diseased state, and for screening treatments for BM-associated diseases and disorders.

Organoid Models

Recently, efforts have been made to produce miniaturized, self-organizing, multicellular, 3D models of the BM niche, termed organoids

[122]. Two parallel articles outline similar multiphase pipelines to produce complex, vascularized organoids that mimic many aspects of the BM microenvironment [112,113]. Each phase of organoid production used a different cocktail of medium components. Initially, iPSCs were encouraged to form embryoid body (EB) aggregates. Once established, the EB aggregates had a mesodermal phenotype induced, which was appropriate as BM niche cells are derived from the mesoderm over ontogeny [80,123]. Next, the EBs were primed for vascular and hematopoietic differentiation and subsequently embedded in a hydrogel. Within the hydrogel, angiogenesis was observed as the EBs began to sprout [124]. Finally, sprouting EBs were removed from the gel and cultured in ultralow adhesion plates, resulting in the formation of vascularized organoids consisting of multiple cell types found within the native BM niche. Organoid models present a unique opportunity to further our understanding of hematologic development over ontogeny using a pluripotent *in vitro* system. In addition, they have shown potential for the maintenance of otherwise difficult to culture primary cancer cells [112] and as pathologic models for diseases such as myelofibrosis and neutropenia [112,113]. Although these models are impressive, future challenges remain in incorporating a complete BM niche cellular cohort and in self-organization into the multiple subniches observed in the *in vivo* BM niche. Moreover, owing to the immaturity of the cells produced, organoid models more closely resemble foetal rather than adult BM. Yet, organoids represent a significant advance in the field; the ease with which iPSCs can be produced compared with other BM stem cell sources makes this an attractive model for HSC expansion and disease modeling, and further optimization of organoid production promises to yield even better *in vitro* BM models.

Similar results were produced using organoid-like constructs termed ossicles, which were assembled *in vitro* and then transplanted into murine models [125,126]. Although these constructs recapitulated some aspects of the BM niche and were subsequently invaded by murine hematopoietic tissue, they still possess many of the issues inherent to animal models compared with fully humanized models [88].

FUTURE OF BM NICHE MODELS

Limitations of Current BM Niche Models

Although the current crop of BM niche models is promising, the challenge remains to produce a system that can consistently expand a population of HSCs without sacrificing the cells' differentiation or engraftment potential. This is in part due to the highly heterogeneous nature of HSCs [127], which makes it difficult to identify LT-HSCs isolated from models [29,47,127,128]. Moreover, LT-HSCs rarely multiply [129], meaning it is likely that any expansion observed occurs out with the LT-HSC compartment, resulting in a population of cells with reduced engraftment and differentiation capacity. Furthering our understanding of hematopoietic niches, especially fetal niches from which HSCs are initially derived [80], could provide an avenue to better understand mechanisms of LT-HSCs expansion, which could in turn allow HSCT treatment to move away from the current one donor one recipient system and toward a one donor multiple recipient system, greatly increasing its availability [130]. Alternatively, simpler approaches to HSC expansion have been used with increasing success in recent years, including the addition of small molecules that prevent loss of the LT-HSC phenotype when expanding

HSCs using cytokine cocktails [72,131,132] and the use of hydrogels for 3D HSC culture [100]. These systems hold great clinical potential, especially nicotinamide-expanded HSCs, which recently gained clinical approval for the HSCs produced to be used for HSCT [92]. The question remains whether the HSCs they generate are adequate replacements for the fresh cells typically used for HSCT, especially when produced at scale. Strategies that blend these simple systems with more complex BM model elements warrant investigation.

Another hurdle for BM model development is the reliance on extracellular stimuli such as perfusion or artificially separated cell populations. This is an adequate compromise while tissue engineering technology continues to develop. However, this approach does not reproduce the complex interplay that occurs within a cellularly diverse, mechanically heterogeneous organ such as the BM niche, not to mention interactions the BM has with other organs within an individual. Fully cellular organoid models, and other emerging approaches discussed further, may offer a revolutionary solution, despite their development still being in its infancy. These systems may pave the way for highly accurate models that can facilitate research on the BM niche and expand understanding of the organ and how it influences hematopoiesis.

Finally, recent advances have led to highly complex BM models that recapitulate various aspects of the native BM niche. These models have furthered our understanding of the cellular and niche signal interplay in this complicated microenvironment. However, this complexity is itself a limitation, owing to the inherent cost, time, and level of expertise required to assemble these models. These challenges must be overcome for BM models to be accepted and more widely used in research and industry.

Potential Applications of BM Niche Models

A prospective application of BM models is their usefulness for studying and developing treatments for BM-associated disorders and diseases. Novel treatments such as chimeric antigen receptor T-cell (CART) therapy show huge promise [133] but are often inaccurately assessed with animal trials owing to differences in animal and human biology, preventing potential treatments from reaching the market or allowing ineffective or unsafe ones to do so [88,134]. Pathologic *in vitro* BM models that more accurately replicate diseased human biology, reduce animal suffering and can be produced at scale have the potential to revolutionize our approach to drug testing, either as a screening step before animal testing or as a complete substitution [135].

BM models have already been used to further our understanding of the BM niche and hematopoiesis, as previously discussed. They have shown that HSC maintenance is reliant on MSCs and the physical properties of the HSC microenvironment, that soluble factors produced by BM cells also play an integral role, and that the BM niche is formed of distinct, interconnected subniches. As BM niche models continue to evolve so will our understanding of the *in vivo* BM niche, hematopoiesis, and HSCs (Figure 2).

Theoretical Future BM Niche Models

Future BM niche models could seek to replicate the *in vivo* niche more accurately by incorporating a complete BM cellular cohort or by precisely replicating the physical, mechanical, and chemical composition of the *in vivo* niche. If achieved, this would result in BM niche models with high biomimicry, furthering our understanding of




Figure 2 Potential applications of a model BM niche. Created with BioRender.com.

the *in vivo* niche's physiology, biochemistry, and biophysics. Other future models could include simplified niches specialized to accomplish a specific goal, such as LT-HSC maintenance [37] and expansion, or as platforms to test novel therapies in which the HSCs are easily accessible for treatment and evaluation [34]. As our understanding of the BM niche continues to develop, it may even become possible to eliminate the need for inherently complex cocultures and replicate the effect of BM cellular components in HSC monoculture systems, simplifying artificial BM niches substantially.

Next-generation models could also be developed. These may include whole-body models that mimic several or all human organs [136], providing a platform for a more comprehensive assessment of a treatment's efficacy and safety on an individual and possibly leading to the development of a body-on-a-chip [137].

In silico models of the BM or whole individuals could also emerge. These might take the form of a digital twin, mimicking the function of biological systems based on experimental data sets and/or biological principles [138]. Simple *in silico* models are already in use and have demonstrated the ability to assist with optimization of experimental parameters [139], confirm hypotheses [140,141], and shed light on previously poorly understood biological systems [142]. Recent advances in artificial intelligence technology could facilitate further development of these revolutionary new models by assisting with data compilation from diverse sources [143] and through utilization of techniques such as deep learning and machine learning to collate and use large data sets for predicting the impact of stimuli such as novel

drugs on biological processes [144]. As such, *in silico* models have the potential to exponentially accelerate research by identifying optimum parameters for experimentation and, with further developments potentially leading to fully realized digital twins, may offer an alternative to animal and *in vitro* models for clinical trials.

One of the key benefits of whole-body next-generation models, both *in silico* and *in vitro*, is their ability to assist with prediction of pharmacokinetics and off-target toxicity, which are not explorable using single organ models [140,145]. Development of these types of models currently remains a challenge as this requires extensive knowledge of the simulated organs or large, reliable, relevant data sets and systems which can interpret and use them. However, owing to the rapidly evolving nature of the field, they may be closer than they appear.

CONCLUSION

Within the past half a century, BM models have gone from simple liquid suspensions of HSCs to highly complex *in vitro* organ models specialized to achieve specific goals. This has greatly improved our understanding of the *in vivo* BM niche, allowing for the exponential pace of BM model development seen recently. As this field continues to develop, it promises to deliver several benefits, namely an improvement over animal models to facilitate more efficacious and cheaper development of treatments for BM-associated disorders and a potential method for the expansion of LT-HSCs for HSCT.

Conflict of Interest Disclosure

The authors declare no conflicts of interests.

Acknowledgments

This work was supported by EPSRC-SFI LifETIME Centre for Doctoral Training (EP/S02347X/1) and EPSRC Grant EP/P001114/1.

REFERENCES

1. Zon LI. Intrinsic and extrinsic control of haematopoietic stem-cell self-renewal. *Nature* 2008;453:306–13.
2. Seita J, Weissman IL. Hematopoietic stem cell: Self-renewal versus differentiation. *Wiley Interdiscip Rev Syst Biol Med* 2010;2:640–53.
3. Wilson A, Laurenti E, Oser G, et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. *Cell* 2008;135:1118–29.
4. Fares I, Calvanese V, Mikkola HKA. Decoding human hematopoietic stem cell self-renewal. *Curr Stem Cell Rep* 2022;8:93–106.
5. Cheshier SH, Morrison SJ, Liao X, Weissman IL. In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. *Proc Natl Acad Sci USA* 1999;96:3120–5.
6. Yamamoto R, Morita Y, Oohara J, et al. Clonal analysis unveils self-renewing lineage-restricted progenitors generated directly from hematopoietic stem cells. *Cell* 2013;154:1112–26.
7. Morrison SJ, Weissman IL. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. *Immunity* 1994;1:661–73.
8. Dykstra B, Kent D, Bowie M, et al. Long-term propagation of distinct hematopoietic differentiation programs in vivo. *Cell Stem Cell* 2007;1:218–29.
9. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. 1961. *Radiat Res* 2011;175:145–9.
10. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkins disease: A randomised trial. *Lancet* 2002;359:2065–71.
11. Locatelli F. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): Results of the EWOG-MDS/EBMT trial. *Blood* 2005;105:410–9.
12. Hulbert ML, Shenoy S. Hematopoietic stem cell transplantation for sickle cell disease: Progress and challenges. *Pediatr Blood Cancer* 2018;65:1–10.
13. Willasch AM, Peters C, Sedláček P, et al. Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study. *Bone Marrow Transplant* 2020;55:1540–51.
14. Busch K, Klapproth K, Barile M, et al. Fundamental properties of unperturbed haematopoiesis from stem cells in vivo. *Nature* 2015;518:542–6.
15. Pietras EM, Mirantes-Barbeito C, Fong S, et al. Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. *Nat Cell Biol* 2016;18:607–18.
16. Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. *Nature* 2014;505:327–34.
17. Nilsson SK, Debatis ME, Dooner MS, Madri JA, Quesenberry PJ, Becker PS. Immunofluorescence characterization of key extracellular matrix proteins in murine bone marrow in situ. *J Histochem Cytochem* 1998;46:371–7.
18. Kunisaki Y, Bruns I, Scheiermann C, et al. Arteriolar niches maintain haematopoietic stem cell quiescence. *Nature* 2013;502:637–43.
19. Acar M, Kocherlakota KS, Murphy MM, et al. Deep imaging of bone marrow shows non-dividing stem cells are mainly perisinusoidal. *Nature* 2015;526:126–30.
20. Pinho S, Frenette PS. Haematopoietic stem cell activity and interactions with the niche. *Nat Rev Mol Cell Biol* 2019;20:303–20.
21. Nichols JE, Cortiella J, Lee J, et al. In vitro analog of human bone marrow from 3D scaffolds with biomimetic inverted colloidal crystal geometry. *Biomaterials* 2009;30:1071–9.
22. Méndez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. *Nature* 2010;466:829–34.
23. De Barros APDN, Takiya CM, Garzoni LR, et al. Osteoblasts and bone marrow mesenchymal stromal cells control hematopoietic stem cell migration and proliferation in 3D in vitro model. *PLoS One* 2010;5:e9093.
24. Tiwari A, Tursky ML, Mushahary D, et al. Ex vivo expansion of haematopoietic stem/progenitor cells from human umbilical cord blood on acellular scaffolds prepared from MS-5 stromal cell line. *J Tissue Eng Regen Med* 2013;7:871–83.
25. Lai WY, Li YY, Mak SK, et al. Reconstitution of bone-like matrix in osteogenically differentiated mesenchymal stem cell-collagen constructs: A three-dimensional in vitro model to study hematopoietic stem cell niche. *J Tissue Eng* 2013;4:1–14.
26. de Lima M, McNiece I, Robinson SN, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. *N Engl J Med* 2012;367:2305–15.
27. Rödling L, Schwedhelm I, Kraus S, Bieback K, Hansmann J, Lee-The-dieck C. 3D models of the hematopoietic stem cell niche under steady-state and active conditions. *Sci Rep* 2017;7:1–15.
28. Bray LJ, Binner M, Körner Y, von Bonin M, Bornhäuser M, Werner C. A three-dimensional ex vivo tri-culture model mimics cell-cell interactions between acute myeloid leukemia and the vascular niche. *Haematologica* 2017;102:1215–26.
29. Futrega K, Atkinson K, Lott WB, Doran MR. Spheroid coculture of hematopoietic stem/progenitor cells and monolayer expanded mesenchymal stem/stromal cells in polydimethylsiloxane microwells modestly improves in vitro hematopoietic stem/progenitor cell expansion. *Tissue Eng Part C Methods* 2017;23:200–18.
30. Bourguine PE, Klein T, Paczulla AM, et al. In vitro biomimetic engineering of a human hematopoietic niche with functional properties. *Proc Natl Acad Sci USA* 2018;115:E5688–95.
31. Aleman J, George SK, Herberg S, et al. Deconstructed microfluidic bone marrow on-a-chip to study normal and malignant hemopoietic cell–niche interactions. *Small* 2019;15:e1902971.
32. Bianco JER, Rosa RG, Congrains-Castillo A, et al. Characterization of a novel decellularized bone marrow scaffold as an inductive environment for hematopoietic stem cells. *Biomater Sci* 2019;7:1516–28.
33. Ma C, Witkowski MT, Harris J, et al. Leukemia-on-a-chip: Dissecting the chemoresistance mechanisms in B cell acute lymphoblastic leukemia bone marrow niche. *Sci Adv* 2020;6:eaba5536.
34. Chou DB, Frismantas V, Milton Y, et al. On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology. *Nat Biomed Eng* 2020;4:394–406.
35. Goranov V, Shelyakova T, De Santis R, et al. 3D patterning of cells in magnetic scaffolds for tissue engineering. *Sci Rep* 2020;10:2289.
36. Nelson MR, Ghoshal D, Mejias JC, Rubio DF, Keith E, Roy K. A multi-niche microvascularized human bone marrow (hBM) on-a-chip elucidates key roles of the endosteal niche in hBM physiology. *Biomaterials* 2021;270:120683.
37. Donnelly H, Ross E, Xiao Y, et al. Bioengineered niches that recreate physiological extracellular matrix organisation to support long-term haematopoietic stem cells. *bioRxiv* 2022.
38. Glaser DE, Curtis MB, Sariano PA, et al. Organ-on-a-chip model of vascularized human bone marrow niches. *Biomaterials* 2022;280:121245.
39. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. *Nature* 2003;425:841–6.
40. Bromberg O, Frisch BJ, Weber JM, Porter RL, Civitelli R, Calvi LM. Osteoblastic N-cadherin is not required for microenvironmental support and regulation of hematopoietic stem and progenitor cells. *Blood* 2012;120:303–13.

41. Greenbaum A, Hsu YM, Day RB, et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. *Nature* 2013;495:227–30.
42. Bowers M, Zhang B, Ho Y, Agarwal P, Chen C-C, Bhatia R. Osteoblast ablation reduces normal long-term hematopoietic stem cell self-renewal but accelerates leukemia development. *Blood* 2015;125:2678–88.
43. Mansour A, Abou-Ezzi G, Sitnicka E, Jacobsen SE, Wakkach A, Blin-Wakkach C. Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow. *J Exp Med* 2012;209:537–49.
44. Zeytin IC, Alkan B, Ozdemir C, Cetinkaya DU, Okur FV. Alterations in hematopoietic and mesenchymal stromal cell components of the osteopetrotic bone marrow niche. *Stem Cells Transl Med* 2022;11:310–21.
45. Hur J, Choi J-L, Lee H, et al. CD82/KAI1 maintains the dormancy of long-term hematopoietic stem cells through interaction with DARC-expressing macrophages. *Cell Stem Cell* 2016;18:508–21.
46. Li D, Xue W, Li M, et al. VCAM-1+ macrophages guide the homing of HSPCs to a vascular niche. *Nature* 2018;564:119–24.
47. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. *Cell* 2005;121:1109–21.
48. Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. *Nature* 2012;481:457–62.
49. Perlman JR, Spörrij A, Zon LI. Blood on the tracks: Hematopoietic stem cell-endothelial cell interactions in homing and engraftment. *J Mol Med* 2017;95:809–19.
50. Braham MVJ, Li Yim ASP, Garcia Mateos J, et al. A human hematopoietic niche model supporting hematopoietic stem and progenitor cells in vitro. *Adv Healthc Mater* 2019;8:e1801444.
51. Heil J, Olsavsky V, Busch V, et al. Bone marrow sinusoidal endothelium controls terminal erythroid differentiation and reticulocyte maturation. *Nat Commun* 2021;12:6963.
52. Stone AP, Nascimento TF, Barrachina MN. The bone marrow niche from the inside out: how megakaryocytes are shaped by and shape hematopoiesis. *Blood* 2022;139:483–91.
53. LeBleu VS, Neilson EG. Origin and functional heterogeneity of fibroblasts. *FASEB J* 2020;34:3519–36.
54. Lee-Thedieck C, Schertl P, Klein G. The extracellular matrix of hematopoietic stem cell niches. *Adv Drug Deliv Rev* 2022;181:114069.
55. Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. *Nature* 2009;460:259–63.
56. Rameshwar P, Gascon P. Substance P (SP) mediates production of stem cell factor and interleukin-1 in bone marrow stroma: Potential autoregulatory role for these cytokines in SP receptor expression and induction. *Blood* 1995;86:482–90.
57. Broome CS, Miyan JA. Neuropeptide control of bone marrow neutrophil production: A key axis for neuroimmunomodulation. *Ann NY Acad Sci* 2000;917:424–34.
58. Katayama Y, Battista M, Kao WM, et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. *Cell* 2006;124:407–21.
59. Lucas D, Scheiermann C, Chow A, et al. Chemotherapy-induced bone marrow nerve injury impairs hematopoietic regeneration. *Nat Med* 2013;19:695–703.
60. Maryanovich M, Zahalka AH, Pierce H, et al. Adrenergic nerve degeneration in bone marrow drives aging of the hematopoietic stem cell niche. *Nat Med* 2018;24:782–91.
61. Xu C, Gao X, Wei Q, et al. Stem cell factor is selectively secreted by arterial endothelial cells in bone marrow. *Nat Commun* 2018;9:2449.
62. Coutu DL, Kokkaliaris KD, Kunz L, Schroeder T. Three-dimensional map of nonhematopoietic bone and bone-marrow cells and molecules. *Nat. Biotechnol.* 2017;35:1202–10.
63. Jansen LE, Birch NP, Schiffman JD, Crosby AJ, Peyton SR. Mechanics of intact bone marrow. *J Mech Behav Biomed Mater* 2015;50:299–307.
64. Chaudhuri O, Cooper-White J, Janmey PA, Mooney DJ, Shenoy VB. Effects of extracellular matrix viscoelasticity on cellular behaviour. *Nature* 2020;584:535–46.
65. Chen X, Hughes R, Mullin N, et al. Mechanical heterogeneity in the bone microenvironment as characterized by atomic force microscopy. *Biophys J* 2020;119:502–13.
66. Spencer JA, Ferraro F, Roussakis E, et al. Direct measurement of local oxygen concentration in the bone marrow of live animals. *Nature* 2014;508:269–73.
67. Ross EA, Turner L-A, Donnelly H, et al. Nanotopography reveals metabolites that maintain the immunosuppressive phenotype of mesenchymal stem cells. *Nat Commun* 2023;14:753.
68. North TE, Goessling W, Peeters M, et al. Hematopoietic stem cell development is dependent on blood flow. *Cell* 2009;137:736–48.
69. Winkler IG, Barbier V, Wadley R, Zannettino ACW, Williams S, Lévesque J-P. Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: Serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. *Blood* 2010;116:375–85.
70. Bixel MG, Kusumbe AP, Ramasamy SK, et al. Flow dynamics and HSPC homing in bone marrow microvessels. *Cell Rep* 2017;18:1804–16.
71. Boitano AE, Wang J, Romeo R, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. *Science* 2010;329:1345–8.
72. Wilkinson AC, Ishida R, Kikuchi M, et al. Long-term ex vivo haematopoietic-stem-cell expansion allows nonconditioned transplantation. *Nature* 2019;571:117–21.
73. Sánchez-Lanzas R, Kalampalika F, Ganuza M. Diversity in the bone marrow niche: Classic and novel strategies to uncover niche composition. *Br J Haematol* 2022;199:647–64.
74. Salmerón-Sánchez M, Dalby MJ. Synergistic growth factor microenvironments. *Chem Commun* 2016;52:13327–36.
75. Xiao Y, Donnelly H, Sprott M, et al. Material-driven fibronectin and vitronectin assembly enhances BMP-2 presentation and osteogenesis. *Mater Today Bio* 2022;16:100367.
76. Leister I, Kramann R, Ventura Ferreira MS, et al. 3D co-culture of hematopoietic stem and progenitor cells and mesenchymal stem cells in collagen scaffolds as a model of the hematopoietic niche. *Biomaterials* 2012;33:1736–47.
77. Wright DE, Wagers AJ, Gulati AP, Johnson FL, Weissman IL. Physiological migration of hematopoietic stem and progenitor cells. *Science* 2001;294:1933–6.
78. Lapidot T, Petit I. Current understanding of stem cell mobilization: The roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. *Exp Hematol* 2002;30:973–81.
79. Patra AK. New aspects of HSC mobilization for better therapeutic outcomes. *Cell Mol Immunol* 2021;18:2583–5.
80. Mikkola HKA, Orkin SH. The journey of developing hematopoietic stem cells. *Development* 2006;133:3733–44.
81. Crane GM, Jeffery E, Morrison SJ. Adult haematopoietic stem cell niches. *Nat Rev Immunol* 2017;17:573–90.
82. Inna CN, Zhou BO, Acar M, et al. A perisinusoidal niche for extramedullary haematopoiesis in the spleen. *Nature* 2015;527:466–71.
83. Gekas C, Dieterlen-Lièvre F, Orkin SH, Mikkola HK. The placenta is a niche for hematopoietic stem cells. *Dev Cell* 2005;8:365–75.
84. Khan JA, Mendelson A, Kunisaki Y, et al. Fetal liver hematopoietic stem cell niches associate with portal vessels. *Science* 2016;351:176–80.
85. Michaels YS, Buchanan CF, Gjorevski N, Moison A. Bioengineering translational models of lymphoid tissues. *Nat Rev Bioeng* 2023;1:731–48.
86. Haas S, Trumpp A, Milsom M D. Causes and consequences of hematopoietic stem cell heterogeneity. *Cell Stem Cell* 2018;22(5):627–38. <https://doi.org/10.1016/j.stem.2018.04.003>.

87. Zhang P, et al. Single-cell RNA sequencing to track novel perspectives in HSC heterogeneity. *Stem Cell Research and Therapy* 2022;13(1):1–15. <https://doi.org/10.1186/s13287-022-02718-1>.
88. Ingber DE. Is it time for reviewer 3 to request human organ chip experiments instead of animal validation studies? *Adv Sci (Weinh)* 2020;7:2002030.
89. Chatterjee C, Schertl P, Frommer M, et al. Rebuilding the hematopoietic stem cell niche: recent developments and future prospects. *Acta Biomater* 2021;132:129–48.
90. Wagner Jr JE, Brunstein CG, Boitano AE, et al. Phase I/II trial of stemregenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft. *Cell Stem Cell* 2016;18:144–55.
91. Meaker GA, Wilkinson AC. Ex vivo hematopoietic stem cell expansion technologies: recent progress, applications, and open questions. *Exp Hematol* 2024;130:104136.
92. Jarosca J, Goltry K, Smith A, et al. Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: Results of a phase I trial using the AastromReplicell system. *Blood* 2003;101:5061–7.
93. Xiao Y, McGuinness CS, Doherty-Boyd WS, Salmeron-Sanchez M, Donnelly H, Dalby MJ. Current insights into the bone marrow niche: From biology in vivo to bioengineering ex vivo. *Biomaterials* 2022;286:121568.
94. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. *Nat Med* 2010;16:232–6.
95. Horwitz ME, Chao NJ, Rizzieri DA, et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. *J Clin Invest* 2014;124:3121–8.
96. Lamprea FP, Carmelo JG, Anjos-Afonso F. Notch signaling in the regulation of hematopoietic stem cell. *Curr Stem Cell Rep* 2017;3:202–9.
97. Asada N, Kunisaki Y, Pierce H, et al. Differential cytokine contributions of perivascular haematopoietic stem cell niches. *Nat Cell Biol* 2017;19:214–23.
98. Sitnicka E, Bryder D, Theilgaard-Mönch K, Buza-Vidas N, Adolfsen J, Jacobsen SEW. Key role of flt3 ligand in regulation of the common lymphoid progenitor but not in maintenance of the hematopoietic stem cell pool. *Immunity* 2002;17:463–72.
99. Qian H, Buza-Vidas N, Hyland CD, et al. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. *Cell Stem Cell* 2007;1:671–84.
100. Bai T, Li J, Sinclair A, et al. Expansion of primitive human hematopoietic stem cells by culture in a zwitterionic hydrogel. *Nat Med* 2019;25:1566–75.
101. Vannini N, Campos V, Girotra M, et al. The NAD-booster nicotinamide riboside potently stimulates hematopoiesis through increased mitochondrial clearance. *Cell Stem Cell* 2019;24:405–418.e7.
102. Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of haematopoietic stem cells in vitro. *J Cell Physiol* 1977;91:335–44.
103. Méndez-Ferrer S, Bonnet D, Steensma DP, et al. Bone marrow niches in haematological malignancies. *Nat Rev Cancer* 2020;20:285–98.
104. Pinho S, Lacombe J, Hanoun M, et al. PDGFR α and CD51 mark human Nestin+ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion. *J Exp Med* 2013;210:1351–67.
105. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. *Science* 1999;284:143–7.
106. Hass R, Kasper C, Böhm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. *Cell Commun Signal* 2011;9:12.
107. Li H, Ghazanfari R, Zacharakis D, Lim HC, Scheduling S. Isolation and characterization of primary bone marrow mesenchymal stromal cells. *Ann NY Acad Sci* 2016;1370:109–18.
108. Bhat S, Viswanathan P, Chandanala S, Prasanna SJ, Seetharam RN. Expansion and characterization of bone marrow derived human mesenchymal stromal cells in serum-free conditions. *Sci Rep* 2021;11:3403.
109. Tsuji W. Adipose-derived stem cells: Implications in tissue regeneration. *World J Stem Cells* 2014;6:312.
110. Li S, Huang K-J, Wu J-C, et al. Peripheral blood-derived mesenchymal stem cells: Candidate cells responsible for healing critical-sized calvarial bone defects. *Stem Cells Transl Med* 2015;4:359–68.
111. Shang Y, Guan H, Zhou F. Biological characteristics of umbilical cord mesenchymal stem cells and its therapeutic potential for hematological disorders. *Front Cell Dev Biol* 2021;9:570179.
112. Khan AO, Rodríguez-Romera A, Reyat JS, et al. Human bone marrow organoids for disease modeling, discovery, and validation of therapeutic targets in hematologic malignancies. *Cancer Discov* 2023;13:364–85.
113. Frenz-Wiessner S, Fairley SD, Buser M, et al. Generation of complex bone marrow organoids from human induced pluripotent stem cells. *Nat Methods* 2024;21:868–81.
114. Dupuis V, Oltra E. Methods to produce induced pluripotent stem cell-derived mesenchymal stem cells: Mesenchymal stem cells from induced pluripotent stem cells. *World J Stem Cells* 2021;13:1094–111.
115. Thanaskody K, Jusop AS, Tye GJ, Zaman WSWK, Dass SA, Nordin F. MSCs vs. iPSCs: Potential in therapeutic applications. *Front Cell Dev Biol* 2022;10:1005926.
116. James S, Fox J, Afsari F, et al. Multiparameter analysis of human bone marrow stromal cells identifies distinct immunomodulatory and differentiation-competent subtypes. *Stem Cell Rep* 2015;4:1004–15.
117. Lewis NS, Lewis EE, Mullin M, Wheadon H, Dalby MJ, Berry CC. Magnetically levitated mesenchymal stem cell spheroids cultured with a collagen gel maintain phenotype and quiescence. *J Tissue Eng* 2017;8:204173141770442.
118. Isem J, Martín-Antonio B, Ghazanfari R, et al. Self-renewing human bone marrow mesospheres promote hematopoietic stem cell expansion. *Cell Rep* 2013;3:1714–24.
119. Lewis EEL, Wheadon H, Lewis N, et al. A quiescent, regeneration-responsive tissue engineered mesenchymal stem cell bone marrow niche model via magnetic levitation. *ACS Nano* 2016;10:8346–54.
120. Gvaramia D, Müller E, Müller K, et al. Combined influence of biophysical and biochemical cues on maintenance and proliferation of hematopoietic stem cells. *Biomaterials* 2017;138:108–17.
121. Raic A, Rödling L, Kalbacher H, Lee-Thedieck C. Biomimetic macroporous PEG hydrogels as 3D scaffolds for the multiplication of human hematopoietic stem and progenitor cells. *Biomaterials* 2014;35:929–40.
122. Rossi G, Manfrin A, Lutolf MP. Progress and potential in organoid research. *Nat Rev Genet* 2018;19:671–87.
123. Vodyanik MA, Yu J, Zhang X, et al. A mesoderm-derived precursor for mesenchymal stem and endothelial cells. *Cell Stem Cell* 2010;7:718–29.
124. Wimmer RA, Leopoldi A, Aichinger M, Kerjaschki D, Penninger JM. Generation of blood vessel organoids from human pluripotent stem cells. *Nat Protoc* 2019;14:3082–100.
125. Reinisch A, Thomas D, Corces MR, et al. A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. *Nat Med* 2016;22:812–21.
126. Reinisch A, Hernandez DC, Schallmoser K, Majeti R. Generation and use of a humanized bone-marrow-ossicle niche for hematopoietic xenotransplantation into mice. *Nat Protoc* 2017;12:2169–78.
127. Rossi L, Challen GA, Sirin O, Lin KK-Y, Goodell MA. Hematopoietic stem cell characterization and isolation. *Methods Mol Biol* 2011;750:47–59.
128. Sonoda Y. Human CD34-negative hematopoietic stem cells: The current understanding of their biological nature. *Exp Hematol* 2021;96:13–26.
129. Zhang P, Zhang C, Li J, Han J, Liu X, Yang H. The physical microenvironment of hematopoietic stem cells and its emerging roles in engineering applications. *Stem Cell Res Ther* 2019;10:1–13.
130. Wilkinson AC, Igarashi KJ, Nakauchi H. Haematopoietic stem cell self-renewal in vivo and ex vivo. *Nat Rev Genet* 2020;21:541–54.

131. Peled T, Shoham H, Aschengrau D, et al. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment. *Exp Hematol* 2012;40:342–355.e1.
132. Cohen S, Bambace N, Ahmad I, et al. Improved outcomes of UM171 –expanded cord blood transplantation compared with other graft sources: Real-world evidence. *Blood Adv* 2023;7:5717–26.
133. Kim MY, Yu K-R, Kenderian SS, et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. *Cell* 2018;173:1439–1453.e19.
134. Akhtar A. The flaws and human harms of animal experimentation. *Camb Q Healthc Ethics* 2015;24:407–19.
135. Haddrick M, Simpson PB. Organ-on-a-chip technology: turning its potential for clinical benefit into reality. *Drug Discov Today* 2019;24:1217–23.
136. Novak R, Ingram M, Clauson S, et al. A robotic platform for fluidically-linked human body-on-chips experimentation. *Nat Biomed Eng* 2020;4:407–20.
137. Sung JH, Wang YI, Sriram NN, et al. Recent advances in body-on-a-chip systems. *Anal Chem* 2019;91:330–51.
138. Geris L, Lambrechts T, Carlier A, Papantoniou I. The future is digital: In silico tissue engineering. *Curr Opin Biomed Eng* 2018;6:92–8.
139. Baker EAG, Schapiro D, Dumitrascu B, Vickovic S, Regev A. In silico tissue generation and power analysis for spatial omics. *Nat Methods* 2023;20:424–31.
140. Chang RL, Xie L, Xie L, Bourne PE, Palsson BØ. Drug off-target effects predicted using structural analysis in the context of a metabolic network model. *PLoS Comput Biol* 2010;6:e1000938.
141. Stratmann AT, Fecher D, Wangorsch G, et al. Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean in silico model. *Mol Oncol* 2014;8:351–65.
142. Edelman LB, Eddy JA, Price ND. In silico models of cancer. *Wiley Interdiscp Rev Syst Biol Med* 2010;2:438–59.
143. Homeyer A, Geißler C, Schwen LO, et al. Recommendations on compiling test datasets for evaluating artificial intelligence solutions in pathology. *Mod Pathol* 2022;35:1759–69.
144. Sarker IH. AI-based modeling: techniques, applications and research issues towards automation, intelligent and smart systems. *SN Comput Sci* 2022;3:158.
145. Bender A, Scheiber J, Glick M, et al. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. *ChemMedChem* 2007;2:861–73.